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Abstract In this double-blind randomised placebo-con-
trolled trial it was investigated during a two-year follow-up
whether oral bisphosphonates (Olpadronate 10 mg/m2/day)
influence quality of life in children with osteogenesis
imperfecta (OI). Thirty-four children with OI (classified
according to Sillence criteria), aged 3 to 18 years of age,
with a restricted level of ambulation were included.
Randomisation was performed using a list of computer
generated random numbers to allocate patients to receive
Olpadronate or placebo. Quality of life was measured using
self-perception profile for children (SPPC) and health-utility
index (HUI). Differences between baseline measurements
and measurements at two years follow-up were analysed
within the Olpadronate and placebo group using a student’s
t-test. Differences in HUI and SPPC regression coefficients
were analysed by random-effects repeated measures analysis
(SAS, Proc Mixed, version 8.2), adjusted for age, gender and
type of OI. Within the Olpadronate group there was a
significant decrease in pain utility; however, difference in six
months’ regression coefficients between the placebo and
Olpadronate group were not significant. Within the placebo
group there was a significant increase in scholastic compe-
tence and behavioural conduct. The item behavioural
conduct showed a steeper annual regression coefficient
favourable for the placebo group. In the other SPPC items
none of the annual regression coefficients showed a
significant difference between the Olpadronate and the
placebo group. Conclusion: We found only slight differences
in quality of life in favour of the bisphosphonate group. A
small but not significant decrease in pain was detected in the
bisphosphonate group.
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Introduction
Assessment of patient-focused health status and quality of
life is recognized increasingly by clinicians, patients
advocates and authorities as primary measures of need,
effectiveness and efficiency in the evaluation of health care
[16]. In orthopaedic surgery the effects of treatment are
conventionally measured by physical function, (e.g. range
of motion, walking distance) [28], whereas quality of life
measures might be important to complement these conven-
tional clinical methods [29]. Quality of life represents the
functional effect of an illness and its consequent therapy
upon a patient, as perceived by the patient [13]. Four
components of the quality of life construct have been
described: physical and occupational function, psycholog-
ical state, social interactions and somatic sensation [34].
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Assessment of burden of morbidity associated with
orthopaedic diagnosis and the effectiveness of clinical
interventions holds especially for chronic diseases. Due to
substantial gains in survival rates in chronic diseases [3],
the prevalence of children with a chronic disease increases,
possibly influencing aspects of quality of life, like physical
and occupational function, psychological state and social
interactions.
Osteogenesis imperfecta (OI) is a heritable disorder of
connective tissue. Most OI types are caused by a defect in
collagen type I synthesis and shows highly variable clinical
expression [6]. OI is subdivided into four types, I, II, III and
IV, based on clinical, radiographic and genetic character-
istics [36]. In OI type I, collagen type I synthesis is
reduced, in OI types II, III and IV, collagen type I synthesis
is reduced and abnormal [40]. Recently, Glorieux et al.
reported that in OI types V, VI and VII there is no evident
mutation in type 1 collagen [21, 22, 39]. Major clinical
characteristics in OI include fragility of bone, osteopenia,
variable degrees of short stature, and progressive skeletal
deformities. Other clinical manifestations include blue
sclerae, dentinogenesis imperfecta, joint laxity and maturi-
ty-onset deafness [32]. In children with OI, consequences
of the disease regarding body function and structure,
activities, participation, as well as internal and external
contextual factors have been described in detail but aspects
of quality of life have been described sparingly [10–12].
Aspects of quality of life (perceived competence) have
been described in children with OI, not treated by medica-
tion, using the self-perception profile for children (SPPC)
[9, 24]. In these children, fair to strong positive perceived
competence was measured. Suskauer et al. recently de-
scribed the temperament in children with OI and concluded
that it did not differ from non-disabled peers [37].
In the past decade, treatment by medication (bisphos-
phonates) in children with OI was initiated. Bisphospho-
nates suppress osteoclast-mediated bone resorption [7].
Many uncontrolled trials have been performed regarding
the influence of bisphosphonates on OI [1, 20, 23].
Recently, two double blind randomised placebo controlled
trials were performed investigating the influence of
bisphosphonates on fracture incidence, functional ability
and bone mineral density. Letchocha et al. found a decrease
in upper extremity fractures without a significant improve-
ment in ambulation and muscle strength [30]. Fracture
incidence in the lower extremity did not change. In our
study group we showed a reduced fracture risk of 30% and
increased lumbar bone mineral density in the bisphospho-
nate group without significant increase in functional ability
level during the follow-up (2 years) as compared to the
placebo group [33]. In this paper the main issue is quality
of life; analyses are focused on unpublished data
concerning quality of life. The severity of osteogenesis
imperfecta was not similar in the two groups which were
randomised prospectively (oral bisphosphonate or placebo).
This might skew the outcome of this study.
The purpose of this study was to investigate whether oral
bisphosphonate therapy might influence aspects of quality of
life in OI children. Our hypothesis was that fewer fractures in
children with OI during bisphosphonate treatment may result
in less pain, and thereby improving quality of life.
Patients and methods
Medical histories of children with skeletal dysplasias were
extracted from a database kept by the Department of
Paediatric Orthopaedic Surgery, Wilhelmina Children’s Hos-
pital of the University Medical Centre Utrecht, The Nether-
lands. Children were eligible for participation in the study if
they had documented OI. To be able to measure a difference
in functional outcome, only children with a restricted level of
ambulation were included. The maximum level of ambula-
tion, measured according to the modified Bleck scale [2, 11],
was “neighbourhood walker without crutches” (maximum
walking distance 250 m). Thirty-seven patients were
approached to participate in the present prospective place-
bo-controlled randomised study with Olpadronate (3-
dimethylamino-1-hydroxypropylidene-1,1-biphosphonate).
One child was not able to take part in the study for religious
reasons and the parents of two children refused for logistical
reasons. Eventually, 16 boys and 18 girls from 3 to 18 years
old were included (13 children with OI type I, 9 with OI type
III, and 12 with OI type IV according to the classification
proposed by Sillence) [36]. Informed consent to participate
was obtained from the parents.
All patients included in this study were seen on a regular
basis in a single-centre, nationwide outpatient multidisci-
plinary unit for children with OI. Children were consecu-
tively randomised independently of their OI type.
Randomisation was performed using a list of computer
generated random numbers to allocate patients to receive
oral Olpadronate in a dose of 10 mg/m2/day or placebo for
a total period of 2 years. Administration of the drugs was
around 7:00 a.m., fasting, half an hour before breakfast, and
in upright position. With regard to possible group incom-
parabilities, we decided not to stratify the randomisation
process but to adjust in the analysis for any baseline
incomparabilities that might occur after randomisation.
Both Olpadronate and placebo were prepared as enteric-
coated tablets by Tiopharma BV, Oud Beyerland, the Nether-
lands. To circumvent any nutritional insufficiencies, all
children received a supplement of 500 mg/m2/day elementary
calcium and 400 IU/day cholecalciferol. Routine care of the
children was continued throughout the study (fracture
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treatment, intra-medullary rodding, corrective osteotomies
scoliosis surgery and rehabilitation when indicated).
The study was approved by the Medical Ethical
Committee of the University Medical Centre Utrecht, the
Netherlands, for a maximum follow-up of 2 years, under
the condition that no children below the age of 3 years were
recruited. Quality of life was measured using the health
utility index-mark III (HUI) [17] and self-perception profile
for children (SPPC) [24, 38]. The HUI questionnaire is a
non-disease specific, generic instrument and applicable in a
wide range of populations and has been extensively used in
Canadian children [4]. Reliability and validity of HUI has
been investigated and validated in Dutch children [19]. The
HUI classification system consists of eight attributes. Each
attribute consists of five to six levels representing the range
of functioning from normal (1) to severely impaired (5 or
6). The attributes forming the HUI system are vision (1–6),
hearing (1–6), speech (1–5), ambulation (1–6), dexterity
(1–6), emotion (1–5), cognition (1–6), and pain (1–5).
Information from the questionnaires was converted to
health state vectors in the HUI formats by an established
algorithm [14]. Single attribute scores of morbidity are
defined on a scale where the worst level has a score of 0
and the best level has a score of 1 [25]. Normative values
are provided by Furlong et al. [15]. In this study, the
attributes pain and ambulation were analyzed. The other
attributes, hearing, speech, dexterity, emotion and cognition
were not analyzed, because they were at maximum level
during inclusion. In this study the parental (proxy)
questionnaire version of the HUI was used. All parents
were instructed by the investigator. This questionnaire was
measured at baseline, and repeated at a six months interval.
Perceived competence was measured using the Harter
self-perception profile for children (SPPC) [24]. The
perceived competence scale has been cross-culturally
validated for Dutch children and normative scores are
available for healthy Dutch children [38]. The SPPC
contains six subscales, taping five specific domains,
scholastic competence, social acceptance, athletic perfor-
mance, physical appearance, behavioural conduct and
global self-worth. The questionnaire consists of 36 items,
6 items for each subscale. Domain scores of perceived
competence are defined on a scale where the worst level is
scored 1 (strongly negative) and the best level is scored 4
(strongly positive). Perceived competence questionnaires
were obtained from the children without parental assistance,
to avoid parental influence concerning the child’s perceived
competence. In children younger than 6 years of age, Harter
pictorial scales of perceived competence were used. Sub-
scales, domains and normal values in the pictorial scale are
different from the questionnaire used in children from 6–12
or 12–18 years of age. Therefore, the SPPC analysis in
children younger than 6 years of age (n=6) was not
involved in analysis. This notwithstanding, these children
were included in this trial because HUI analysis was
applicable for this age. Other parameters measured in these
young children were suitable for analysis and have already
been published [33].
The fracture incidence was scored using new radiolog-
ically confirmed non-vertebral fractures.
All data were gathered by the first author (HJK).
Drug tolerability and compliance
Prior to the study, children and parents were informed about
the occasional occurrence of gastrointestinal side effects
reported with the use of any bisphosphonate (regurgitation,
heartburn, and upper abdominal discomfort). In the Olpadr-
onate group no side effects like esophagitis were reported.
In the placebo-group one child suffered upper abdominal
discomfort of unknown origin, which disappeared sponta-
neously within one week. Parents returned empty boxes to
the investigator during outpatient clinic visit. In the
Olpadronate group bone mineral density significantly
increased compared to the controls [33]. This bisphospho-
nates effect has been reported extensively [1, 20, 23] and
confirms compliance in the Olpadronate group.
Statistical analysis
Differences between baseline measurements and two-year
follow-up regarding HUI and SPPC were analyzed within
the Olpadronate and placebo groups using a student’s t-test.
Differences in six months’ interval (repeated every 6 months)
of HUI scores between the Olpadronate and placebo groups
were analyzed by random-effects repeated-measures analy-
sis (SAS, Proc Mixed, version 8.2). Differences in one year’s
interval (repeated every year) of SPCC scores between the
Olpadronate and placebo groups were analyzed by random-
effects repeated-measures analysis (SAS, Proc Mixed,
version 8.2). The correlation between the total number of
fractures during the trial, mean pain score (HUI) and mean
Table 1 Baseline characteristics
Olpadronate (n=16) Placebo (n=18)
Mean age (sd),
years
10.0 (3.1) (3 to
15 years)
10.7 (3.9) (4 to
16 years)
Male/female (n) 9/7 7/11
Osteogenesis imperfecta type (n)
Type I 4 9
Type III 4 5
Type IV 8 4
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ambulation level (HUI) in treatment and placebo group, was
analysed by Spearman’s correlation coefficient.
Differences are expressed as regression coefficient and
95% confidence interval (95% CI), and adjustment for age,
OI type and gender was performed.
Results
Group differences in age, OI type and gender are presented
in Table 1. One patient in the placebo group withdrew
3 months after randomisation for reasons of motivation and
logistics. Another patient who had been assigned to the
Olpadronate group encountered a clinical discussion during
follow-up about specific features of his bone disorder, and
his parents stopped medication at 18 months’ follow-up.
Two children, one in each group, showed suboptimum
adherence since they forgot to take medication once a week
on average. No child reported signs or symptoms of an
acute-phase reaction.
Mean values of SPPC at start and follow-up were equal
or above the mean level for Dutch healthy children [38] in
both the placebo and Olpadronate groups (Table 2), with
the exception of athletic performance. Differences in annual
regression coefficients between the Olpadronate and place-
bo groups are described in Table 3. In the placebo group a
significant increase in scholastic competence and behav-
ioural conduct was found. The item behavioural conduct
showed a steeper annual regression coefficient (0.23)
favourable for the placebo group, after adjustment for age,
sex and type of OI. In the other items no annual regression
coefficients showed a significant difference between the
Olpadronate and placebo groups, either unadjusted or
adjusted for age, sex and type of OI.
Mean values of HUI pain utility and ambulation were
around level 2 (0.92), indicating mild to moderate pain that
prevents no activities, and just above level 3 (0.63),
respectively, which means able to walk around the
neighbourhood with walking equipment, but without the
help of another person.
Differences between the first and last measurements in
HUI were calculated within the Olpadronate and placebo
group (Table 4). Within the Olpadronate group there was a
significant decrease in pain utility. Differences in six
months’ regression coefficient regarding the utilities ambu-
lation and pain are given in Table 5. None of these six
months’ regression coefficients showed a significant differ-
ence, either unadjusted or adjusted for age, sex and type of
OI. In the remaining items of HUI it was not possible to
calculate six months’ regression coefficients because the
items did not change during follow-up. Six children on
Olpadronate (40%) and 5 children on placebo (29%) had no
fractures throughout the study. In the Olpadronate group,
four children had 1 fracture, one had 2, one had 3, two had
4 and one child had 5 fractures. Fifteen fractures had
occurred during the first year and 7 during the second year
of the study. In the placebo group, two children had 1
fracture, one had 2, three had 3, one had 4, two had 5, one
had 7, one had 8, and one child had 10 fractures. Twenty-
four had occurred during the first year and 28 during the
Table 2 Mean values (sd) of SPPC scores at start of the trial and at two-year follow-up in Olpadronate and placebo children
SPPC outcomes (n=28) Olpadronate Placebo
0 years mean (sd) 2 years mean (sd) 0 years mean (sd) 2 years mean (sd)
Scholastic competence 2.97 (0.61) 3.19 (0.47) 3.00 (0.59) 3.45 (0.60)*
Athletic performance 2.39 (0.59) 2.38 (0.75) 2.36 (0.66) 2.58 (0.69)
Social acceptance 3.14 (0.60) 3.23 (0.38) 3.36 (0.74) 3.66 (0.30)
Physical appearance 3.14 (0.58) 3.12 (0.76) 2.78 (0.77) 3.00 (0.51)
Behavioural conduct 3.32 (0.44) 3.39 (0.44) 2.66 (0.48) 3.20 (0.42)*
Global self-worth 3.55 (0.44) 3.61 (0.46) 3.23 (0.46) 3.43 (0.66)
*p-value<0.05; score 1 represents the worse score and 4 the best score
Table 3 Mean differences in perceived competence in OI children











−0.08 (−0.26 to 0.11) −0.07 (−0.26 to 0.11)
Athletic
performance
−0.13 (−0.35 to 0.10) −0.12 (−0.36 to 0.10)
Social
acceptance
−0.11 (−0.36 to 0.13) −0.11 (−0.35 to 0.13)
Physical
appearance
−0.09 (−0.33 to 0.15) −0.09 (−0.34 to 0.15)
Behavioural
conduct
−0.23 (−0.44 to −0.02) * −0.23 (−0.43 to −0.02) *
Global self-
worth
−0.06 (−0.25 to 0.12) −0.06 (−0.25 to 0.12)
*p<0.05; adjusted for age, gender and type of OI
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second year of the study. Olpadronate therapy resulted in 25
percent relative fracture risk reduction.
In the Olpadronate group no significant correlations were
found between pain (HUI) and number of fractures in
2 years, whereas in the placebo group a moderate significant
correlation was found (−0.48, p=0.046) (Table 6).
Discussion
We found little difference in quality of life between the
bisphosphonate and placebo groups however in favour of
the bisphosphonate group during the two-year follow-up.
The small number of children included might be a limiting
factor in this study. It was not possible to include more
children with OI in the Netherlands who met our inclusion
criteria. SPPC levels at start and follow-up were equal or
above the mean level for Dutch healthy children [38] in
both the placebo and Olpadronate group (Table 2). This
high level of SPPC baseline measurement makes it difficult
to measure a statistical significant improvement. Within the
Olpadronate group there was a very small, significant
decrease in pain. Within the placebo group scholastic
competence and behavioural conduct increased during
follow-up, this might be due to maturation [35]. Remark-
ably, a significant difference was found in annual change
concerning behavioural conduct, favourable for the placebo
group. We cannot explain the different development
between the two groups in behavioural conduct, in this
small study it might be an artifact. Olpadronate was chosen
because it is one of the more potent nitrogen-containing
bisphosphonates, and the efficacy and safety of the drug
was investigated in growing children [5, 27]. Furthermore,
oral medication is preferred in placebo-controlled studies
and oral bisphosphonates have shown to be equally
effective as intravenous bisphosphonates [8]. Its potency
in terms of antiresorptive efficacy is comparable to that of
Alendronate and Residronate [7].
Part of the results of this study, concerning bone mineral
density, functional ability and fracture incidence during the
trial, were reported earlier [33]. We may conclude that
Olpadronate in a daily dosage of 10 mg/m2 has a
measurable clinical effect since an increased bone mineral
density and lower fracture incidence favourable in the
Olpadronate group were found [33]. If Olpadronate had
clearly influenced quality of life, we probably would have
measured this.
There is a discrepancy in outcomes on quality of life
between the reports of uncontrolled studies and controlled
studies with bisphosphonates. In other randomised controlled
trials with bisphosphonate therapy, an increased BMD and
decreased fracture incidence did not clearly influence pain
level as well [18, 30]. On the other hand, in several
uncontrolled studies in children with OI treated with
bisphosphonates, beneficial effects in terms of pain level as
measured by a VAS score were reported [20, 23, 31, 41].
Table 4 Mean values (sd) of HUI scores at start and follow-up in Olpadronate and placebo children
Health utility index outcomes (n=34) Olpadronate Placebo
0 years mean (sd) 2 years mean (sd) 0 years mean (sd) 2 years mean (sd)
Pain 0.95 (0.06) 0.98 (0.03)* 0.95 (0.76) 0.96 (0.04)
Ambulation 0.73 (0.13) 0.74 (0.16) 0.70 (0.19) 0.74 (0.16)
Vision 0.99 (0.01) 1.00 (0.01) 0.99 (0.01) 0.99 (0.01)
Hearing 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 1.00 (0.00)
Dexterity 0.98 (0.06) 1.00 (0.00) 0.99 (0.02) 1.00 (0.01)
Emotion 0.99 (0.02) 0.99 (0.02) 0.99 (0.02) 0.99 (0.02)
Cognition 0.99 (0.02) 1.00 (0.01) 1.00 (0.02) 0.99 (0.03)
Speech 1.00 (0.02) 0.99 (0.03) 1.00 (0.01) 1.00 (0.00)
*p<0.05, significant change in two years within the group; range of score between 0 and 1 indicating minimum and maximum scores
Table 5 Mean differences between the Olpadronate and placebo








Ambulation 0.013 (−0.02, 0.05) 0.01 (−0.02 to 0.05)
Pain −0.01 (−0.03 to 0.00) −0.01 (−0.03 to 0.00)
Adjusted for age, gender and type of OI





Number of fractures and pain (HUI) −0.06 −0.48 *
Number of fractures and ambulation (HUI) 0.03 0.12
Pain (HUI) and ambulation (HUI) 0.14 0.03
*p-value<0.05
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In these non-controlled trials the beneficial effect of
bisphosphonate on pain level was explained by a decreased
fracture incidence [20, 23, 31, 41]. Within our treatment
group a very slight significant decrease in pain level was
measured at the end of the study; however, at six months’
interval regression coefficients did not differ between the
two groups. In this study pain level was measured by HUI
parental (proxy) questionnaire. It might be possible that a
discrepancy between observed pain by the parents and pain
level in the child’s opinion existed. Perception of quality of
life from the perspectives of patients, parents and paedia-
tricians as measured by HUI has been investigated by Janse
et al. [26]. They mentioned that children perceived more
pain than parents observed [26]. When using the HUI in our
study, it might therefore have been possible that a discrep-
ancy between the observed pain by the parents and the pain
level in the child’s opinion existed. Another intrinsic
limitation of the study was that it was not possible to
analyse the complete follow-up of SPPC assessment by the
child itself, because some children were too young to fill in
the form or were not able to read Dutch comprehensively.
One item of the SPPC behaviour showed a different
annual coefficient favourable for the Olpadronate group.
We cannot explain by which mechanism bisphosphonates
might influence behaviour.
In another aspect of quality of life, athletic performance
(SPCC) and ambulation level (HUI), no difference was
found during two years of follow-up. This is in concor-
dance with our previous reported results on functional
ability [33].
Bisphosphonate therapy results in a decreased fracture
incidence, which results in decreased surgical interventions
and consecutive hospitalisation and immobilisation. It is
possible that quality of life ameliorates after a follow-up
period longer than 2 years; a longer interval without
fractures and immobilisation might be necessary to improve
quality of life. If our study group would have been larger,
results concerning quality of life might have been more
pronounced. In our study it was not possible to recruit more
children with OI who were registered in the Netherlands. In
the placebo group, Spearman’s correlation coefficient
between number of fractures and pain was significant,
children who suffered more fractures during two years of
follow-up, suffered more pain as well. No correlation was
found in the Olpadronate group, possibly the lower number
of fractures made correlations less clear. Another explana-
tion is that a low pain level, especially in the bisphospho-
nates group, made the correlation between the number of
fractures and pain level less clear. Following randomisation,
there was a relatively greater amount of children with a
more severe form of OI in the Olpadronate group (12 of 16
children with types III and IV OI, 75%), as compared to the
placebo group (9 of 18 children with types III and IV OI,
50%). Although we adjusted for OI type, this might have
influenced results concerning quality of life, ambulation
level and athletic performance. In types III and IV OI, a
plateau phase in functional ability has been described [10].
Therefore it might be difficult to find a possible improve-
ment in athletic performance and ambulation level in the
Olpadronate group, since 75% of the children in this group
have OI type III or IV.
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